Open Access
Issue
Med Buccale Chir Buccale
Volume 21, Number 3, juillet 2015
Page(s) 149 - 155
Section Article pédagogique / Educational article
DOI https://doi.org/10.1051/mbcb/2015025
Published online 06 July 2015
  1. Sibaud V, Boralevi F, Vigarios E, Fricain JC. Oral toxicity of targeted anticancer therapies. Ann Dermatol Venereol 2014; 141:354-63. [CrossRef] [PubMed] [Google Scholar]
  2. Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 2011;47:441-8. [CrossRef] [PubMed] [Google Scholar]
  3. Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012;17:135-44. [CrossRef] [PubMed] [Google Scholar]
  4. Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer 2012; 48:340-6. [CrossRef] [PubMed] [Google Scholar]
  5. Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013;49:293-8. [CrossRef] [PubMed] [Google Scholar]
  6. Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol 2011; 6:125-9. [CrossRef] [PubMed] [Google Scholar]
  7. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010;116:210-5. [PubMed] [Google Scholar]
  8. Fricain JC, Cellerié K, Sibaud V, Catros S, Taïeb A, Merville P. Oral ulcers in kidney allograft recipients treated with sirolimus. Ann Dermatol Venereol 2008;135:737-41. [CrossRef] [PubMed] [Google Scholar]
  9. Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59:526-40. [CrossRef] [PubMed] [Google Scholar]
  10. Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C, et al. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. Eur J Oncol Nurs 2012;16:172-84. [CrossRef] [PubMed] [Google Scholar]
  11. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045-51. [CrossRef] [PubMed] [Google Scholar]
  12. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657-70. [CrossRef] [PubMed] [Google Scholar]
  13. Elting LS, Chang YC, Parelkar P, Boers-Doets CB, Michelet M, Hita G, et al. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer 2013;21:3243-54. [CrossRef] [PubMed] [Google Scholar]
  14. Pryor DI, Porceddu SV, Burmeister BH, Guminski A, Thomson DB, Shepherdson K, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 2009;90:172-6. [CrossRef] [PubMed] [Google Scholar]
  15. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009;115:1286-99. [CrossRef] [PubMed] [Google Scholar]
  16. Gómez Fernández C, Sendagorta Cudós E, Casado Verrier B, Feito Rodríguez M, Suárez Aguado J, Vidaurrázaga Díaz de Arcaya C. Oral lichenoid eruption associated with imatinib treatment. Eur J Dermatol 2010;20:127-8. [PubMed] [Google Scholar]
  17. Basso FG, Boer CC, Correa MEP, Torrezan M, Cintra ML, Gallotini de Magalhaes MHC, et al. Skin and oral lesions associated to imatinib mesylate therapy. Support Care cancer 2009;17:465-8. [CrossRef] [PubMed] [Google Scholar]
  18. Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol 2006;45:1471-3. [CrossRef] [PubMed] [Google Scholar]
  19. Kuten-Shorrer M, Hochberg E, Woo SB. Lichenoid mucosal reaction to rituximab. Oncologist 2014;19:e12-e13. [CrossRef] [PubMed] [Google Scholar]
  20. Vigarios E, Lamant L, Delord JP, Fricain JC, Chevreau C, Barrés B, et al. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors. Br J Dermatol 2015;172:1680-2. [CrossRef] [PubMed] [Google Scholar]
  21. Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma. Oncologist 2013;18:314-2. [CrossRef] [PubMed] [Google Scholar]
  22. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013;24:1691-7. [CrossRef] [PubMed] [Google Scholar]
  23. Sibaud V, Lamant L, Maisongrosse V, Delord JP. Adverse skin reactions induced by BRAF inhibitors: a systematic review. Ann Dermatol Venereol 2013;140:510-20. [CrossRef] [PubMed] [Google Scholar]
  24. Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, et al. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res 2014;74:2238-45. [CrossRef] [PubMed] [Google Scholar]
  25. Pileri A, Cricca M, Gandolfi L, Misciali C, Casadei B, Zinzani PL, et al. Vemurafenib mucosal side-effect. J Eur Acad Dermatol Venereol. 2015 Mar 12. doi: 10.1111/jdv.13105. [Google Scholar]
  26. Gavrilovic IT, Balagula Y, Rosen AC, Ramaswamy V, Dickler MN, dunkel IJ, et al. Characteristics of oral mucosal events related to bevacizumab treatment. The Oncologist 2012;17: 274-8. [CrossRef] [PubMed] [Google Scholar]
  27. Hubiche T, Valenza B, Chevreau C, Fricain JC, Del Giudice P, Sibaud V. Geographic tongue induced by angiogenesis inhibitors. Oncologist 2013;18:e16-7. [CrossRef] [PubMed] [Google Scholar]
  28. Vigarios E, de Bataille C, Boulanger M, Fricain JC, Sibaud V. Variations physiologiques de la langue. Annales de dermatologie et vénérologie, à paraître 2015. [Google Scholar]
  29. Sibaud V, Fricain JC, Baran R, Robert C. Pigmentary disorders induced by anticancer agents. Part I: chemotherapy. Ann Dermatol Venereol 2013;140:183-96. [CrossRef] [PubMed] [Google Scholar]
  30. Mattsson U, Halbritter S, Mörner Serikoff E, Christerson L, Warfvinge G. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:e12-6. [CrossRef] [Google Scholar]
  31. Li CC, Malik SM, Blaeser BF, Dehni WJ, Kabani SP, Boyle N, et al. Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol 2012; 6:290-5. [CrossRef] [PubMed] [Google Scholar]
  32. Sibaud V, Robert C. Anomalies pigmentaires induites par les traitements anticancéreux. Deuxième partie : les thérapies ciblées. Ann Dermatol Venereol 2013;140: 266-73. [CrossRef] [PubMed] [Google Scholar]
  33. Sibaud V, Vigarios E, Combemale P, Lamant L, Lacouture ME, Lacaze JL, et al. T-DM1-related telangiectasias: a potential role in secondary bleeding events. Ann Oncol 2015;26:436-7. [CrossRef] [PubMed] [Google Scholar]
  34. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76: 209-11. [CrossRef] [PubMed] [Google Scholar]
  35. Nicolatou-Galitis O, Migkou M, Psyrri A, Bamias A, Pectasides D, Economopoulos T, et al. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:234-8. [CrossRef] [PubMed] [Google Scholar]
  36. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012;107:1665-71. [CrossRef] [PubMed] [Google Scholar]
  37. Chimiothérapie et soins bucco-dentaires. Référentiels inter régionaux en soins oncologiques de support, AFSOS 2010 en ligne : http://www.afsos.org/IMG/pdf/Chimiothrapie_et_soins_ buccodentaires-2.pdf [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.